Pfizer Stock - Analyst consensus and valuation snapshot

Pfizer stock remains under watch as analysts reassess earnings expectations, valuation and dividend support after the post-COVID reset. Wall Street’s consensus still points to moderate upside, while investors scrutinize cash flows and the late-stage pipeline.

Edited by ad hoc news Background & Management Desk. Verified prior to publication on 06/21/2026, 07:27 CET. Details in the imprint.

Pfizer (US7170811035) is back in the analyst spotlight as investors reassess earnings power, valuation and its sizeable dividend after the COVID windfall faded. The latest consensus data suggest modest upside from current levels, with a broadly neutral stance on the stock, according to recent analyst and valuation overviews from MarketWatch and Simply Wall St.

What recent analyst data show

Wall Street broadly keeps a "Hold" stance on Pfizer stock, with an average 12-month price target in the high-$20s per share, according to recent consensus summaries such as Simply Wall St’s valuation review. Analysts see potential total return supported mainly by the dividend rather than rapid earnings growth.

The same overview points to a fair value estimate around $28 per share against a spot price near the mid-$20s, implying Pfizer could trade at a discount of roughly 10% to 20%, based on aggregate discounted cash flow and peer multiple methods described in the analysis.

How consensus frames the outlook

Recent consensus commentary emphasizes Pfizer’s pivot away from exceptional COVID revenues toward its core vaccines, oncology and immunology franchises, while cost savings and portfolio pruning are intended to protect margins. Analyst notes highlight that execution on new launches will be key to stabilizing earnings and eventually returning to growth.

Pfizer’s dividend yield stands clearly above the broader market, which many analysts see as a cushion while the company works through its so-called patent cliff and integrates recent deals. At the same time, several reports stress that the yield alone does not offset the need for visible, sustainable earnings momentum over the medium term.

How the company makes money

Pfizer generates most of its revenue from prescription medicines and vaccines in areas such as oncology, cardiovascular disease, infectious diseases and immunology. Key products include Eliquis for stroke prevention, the Prevnar pneumococcal vaccine line and newer launches from its oncology portfolio, alongside a large late-stage research pipeline.

Where the stock trades today

Pfizer shares (US7170811035) trade on the New York Stock Exchange at around $25 per share as of 06/21/2026, 07:27 CET.

Key facts on Pfizer stock

• Company: Pfizer Inc.
• ISIN: US7170811035
• WKN: 852009
• Ticker: PFE
• Venue: NYSE
• Price (as of 06/21/2026, 07:27 CET): 25.00 USD
• Market cap: 143,700,000,000 USD (as of 06/21/2026)
• Sector / Industry: Health Care / Pharmaceuticals
• Index membership: S&P 500
• Next earnings date: not officially scheduled

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.